Equity and dividends
As per December 31st 2013, the company reported on equity of NOK 77 million. On December 20th 2013, the Board of Directors of the Company resolved to carry out a right issue of NOK 3,6 million by issuing 482 113 new shares with a nominal value of NOK 3 each at a subscription price per share of NOK 7,5. The share issue was registered December 30th 2013 with the Norwegian Register of Business Enterprises. On February 11th 2014, the settlement for the purchase of Vitasynth Ltd was finalized through an issue of 2 336 000 NattoPharma shares to the seller Novel Nutrition Network Ltd for the remaining 66 % ownership together with a cash payment of Euro 175 000. As per February 11th 2014, the total number of shares issued is 12 038 909 each with a face value of NOK 3 and the total share capital is NOK 36.1 million.
The Board of Directors continuously assesses the working capital and investment capital needed to meet future growth, especially within the field of pharma, and has considered this to be more important than paying dividends. However, a policy of not paying dividends has not been adopted by the Board.
No dividends have been paid to the Company’s shareholders for the period 2004 - 2012.